🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

RecruitingPhase 4Ages any - anyAllFudan University
NCT06195228 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer. The retrospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 participated hospitals from January 2020 to December 2023 were retrieved. The number of previous treatment lines was not limited. Patients who met the inclusion criteria were screened according to the inclusion and exclusion criteria. Demographic information, clinical characteristics, tumor treatment history, medication regimen, adverse reactions, molecular test results, survival follow-up results and other data were collected. The prospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 Chinese hospitals from January 2024 to April 2027 were enrolled.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Patients volunteered to participate in this study and signed informed consent; 2. Each center can be enrolled in patients who meet the age of their own practice range, regardless of gender ; 3. Histologically diagnosed locally advanced or recurrent / metastatic thyroid cancer that cannot undergo radical surgery meets one of the following requirements: 1. Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC); 2. Differentiated thyroid carcinoma not suitable for iodine therapy; 3. Medullary thyroid carcinoma (MTC); 4. poorly differentiated thyroid cancer (PDTC) or anaplastic thyroid cancer (ATC); 4. Thyroid-related pathogenic or therapeutic target gene detection was performed before enrollment. Exclusion Criteria: 1. Patients who are participating in clinical trials of other drugs; 2. There is evidence that the patients are pregnant or lactating; 3. Other situations that are not suitable for inclusion in this study.
💊

What it tests

  • dabrafenib plus trametinib with or without PD-1 antibody
  • entrectinib or larotrectinib with or without anti-PD-1 antibdoy
  • pralsetinib or selpercatinib with or without anti-PD-1 antibdoy
  • anlotinib or anlotinib plus anti-PD-1 antibody
  • lenvatinib plus anti-PD-1 antibody
📍

Where

8 sites
Fujian Cancer Hospital
Fuzhou, China
Henan Cancer Hospital
Zhengzhou, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
Caixia Liu
Hohhot, China
Fudan University Shanghai Cancer Center
Shanghai, China
Shanxi Cancer Hospital
Shanxi, China
Zhejiang Cancer Hospital
Hangzhou, China
Peking union medical college hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy